Orphazyme agrees to sell itself, and its 'pipeline-in-a-product,' to KemPharm

KemPharm has agreed to acquire Orphazyme and all assets and operations, the companies announced Sunday evening, including the once-hyped drug candidate arimoclomol. KemPharm will pay $12.8 million in cash for the transaction and assume liabilities equal to about $5.2 million. The deal is expected to close before June 1.